The global Non-Small Cell Lung Cancer Market is estimated to be valued at US$ 27,252.31 Mn in 2023 and is expected to exhibit a CAGR of 9.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. It develops in the cells lining the alveoli in the lungs. NSCLC comprises approximately 85% of all lung cancers and includes adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Early detection of NSCLC is crucial for improved treatment outcomes.
Market key trends:
Emerging new technologies for NSCLC diagnosis and treatment, such as artificial intelligence, are contributing significantly to the growth of the non-small cell lung cancer market. Artificial intelligence algorithms can analyze complex medical imaging data, like CT scans, and detect lung cancers with high accuracy. They also provide prognosis of cancer stages which helps doctors customize treatment plans. Such technological advancements are enabling early detection of NSCLC, improving treatment outcomes and boosting the demand for non-small cell lung cancer diagnostics and therapeutics.
Segment Analysis
The global non-small cell lung cancer market size is segmented by disease type, treatment type, end user and region. By disease type, the squamous cell carcinoma segment dominated the market in 2022 due to high prevalence. Squamous cell carcinoma accounts for about 25-30% of all lung cancer cases. By treatment type, the chemotherapy segment accounted for the largest share as chemotherapy is the primary treatment approach for NSCLC.
Key Takeaways
The global non-small cell lung cancer market size was valued at US$ 27252.31 Mn in 2023 and is expected to grow at a CAGR of 9.4% during the forecast period. Driven by rising tobacco consumption and increasing air pollution across emerging economies.
Regional analysis: North America dominated the global non-small cell lung cancer market in 2023 and is expected to maintain its dominance over the forecast period. This is attributed to increasing prevalence of lung cancer and growing adoption of advanced technologies in the region.
Key players: Key players operating in the non-small cell lung cancer market include Pfizer Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Boehringer Ingelheim GMBH, Novartis AG, Bristol-Myers Squibb Company, and Merck & Co., Inc. Pfizer Inc. dominates the market with its newer drugs launched for NSCLC treatment.
Get more insights on this topic: https://www.newsstatix.com/non-small-cell-lung-cancer-market-size-and-opportunity/
Comments
0 comment